David E Szymkowski

Summary

Affiliation: Xencor Inc
Country: USA

Publications

  1. ncbi request reprint Chemical genomics versus orthodox drug development
    David E Szymkowski
    Xencor, 111 West Lemon Avenue, Monrovia CA 91016, USA
    Drug Discov Today 8:157-9. 2003
  2. ncbi request reprint Rational optimization of proteins as drugs: a new era of 'medicinal biology'
    David E Szymkowski
    Drug Discov Today 9:381-3. 2004
  3. ncbi request reprint Timely lessons for target-based discovery of anti-inflammatory drugs
    David E Szymkowski
    Xencor, Monrovia, CA 91016, USA
    Drug Discov Today 10:14-7. 2005
  4. ncbi request reprint Creating the next generation of protein therapeutics through rational drug design
    David E Szymkowski
    Xencor Inc, 111 West Lemon Avenue, Monrovia, CA 91016, USA
    Curr Opin Drug Discov Devel 8:590-600. 2005
  5. ncbi request reprint Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection
    Jonathan Zalevsky
    Xencor, Monrovia, CA 91016, USA
    J Immunol 179:1872-83. 2007
  6. doi request reprint Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics
    Isabelle Maillet
    Laboratory of Molecular Immunology and Embryology, University of Orleans, Orleans, France
    Am J Respir Cell Mol Biol 45:731-9. 2011
  7. ncbi request reprint Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
    Paul M Steed
    Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA
    Science 301:1895-8. 2003

Collaborators

  • John R Desjarlais
  • Jost Vielmetter
  • MALU G TANSEY
  • Jonathan Zalevsky
  • Paul M Steed
  • Isabelle Maillet
  • Bernhard Ryffel
  • Francois Erard
  • CHRISTOPHER O'BRIEN
  • Araz Eivazi
  • Duc Hanh T Nguyen
  • James Kung
  • Stephen K Doberstein
  • Sebastien Fleury
  • Rene Moser
  • Isabelle Couillin
  • Akira Kanda
  • Valerie F J Quesniaux
  • David Dombrowicz
  • Silvia Schnyder-Candrian
  • Thomas Secher
  • Sergei A Ezhevsky
  • Laure Janot
  • Donald O'Keefe
  • Lisa Cherry
  • Hyo H Chung
  • David Carmichael
  • Sean C Yoder
  • Peter Cheung
  • Bassil I Dahiyat
  • Alice Kim
  • Umesh S Muchhal
  • Christina Abbott
  • Marian Hwang
  • Esther Kim
  • Cheryl Chan
  • Sarah X Gao
  • Omid Vafa
  • Eugene A Zhukovsky
  • Linus Hyun
  • Sandhya Kashi
  • Karen Singer
  • Anton V Filikov
  • Sabrina P Martinez
  • Arthur J Chirino
  • RenĂ© S Hubert

Detail Information

Publications7

  1. ncbi request reprint Chemical genomics versus orthodox drug development
    David E Szymkowski
    Xencor, 111 West Lemon Avenue, Monrovia CA 91016, USA
    Drug Discov Today 8:157-9. 2003
  2. ncbi request reprint Rational optimization of proteins as drugs: a new era of 'medicinal biology'
    David E Szymkowski
    Drug Discov Today 9:381-3. 2004
  3. ncbi request reprint Timely lessons for target-based discovery of anti-inflammatory drugs
    David E Szymkowski
    Xencor, Monrovia, CA 91016, USA
    Drug Discov Today 10:14-7. 2005
  4. ncbi request reprint Creating the next generation of protein therapeutics through rational drug design
    David E Szymkowski
    Xencor Inc, 111 West Lemon Avenue, Monrovia, CA 91016, USA
    Curr Opin Drug Discov Devel 8:590-600. 2005
    ....
  5. ncbi request reprint Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection
    Jonathan Zalevsky
    Xencor, Monrovia, CA 91016, USA
    J Immunol 179:1872-83. 2007
    ....
  6. doi request reprint Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics
    Isabelle Maillet
    Laboratory of Molecular Immunology and Embryology, University of Orleans, Orleans, France
    Am J Respir Cell Mol Biol 45:731-9. 2011
    ....
  7. ncbi request reprint Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
    Paul M Steed
    Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA
    Science 301:1895-8. 2003
    ..Similar rational design could be used to engineer inhibitors of additional TNF superfamily cytokines as well as other multimeric ligands...